After Today’s Big Increase, Is AveXis, Inc. (AVXS)’s Near-Term Analysis Positive?

December 7, 2017 - By Jacob Falcon

The stock of AveXis, Inc. (NASDAQ:AVXS) is a huge mover today! The stock increased 7.32% or $6.73 during the last trading session, reaching $98.7. About 449,817 shares traded or 26.32% up from the average. AveXis, Inc. (NASDAQ:AVXS) has risen 95.85% since December 7, 2016 and is uptrending. It has outperformed by 79.15% the S&P500.
The move comes after 8 months positive chart setup for the $3.16B company. It was reported on Dec, 7 by Barchart.com. We have $102.65 PT which if reached, will make NASDAQ:AVXS worth $126.24 million more.

Analysts await AveXis, Inc. (NASDAQ:AVXS) to report earnings on March, 15. They expect $-1.21 earnings per share, down 31.52 % or $0.29 from last year’s $-0.92 per share. After $-1.52 actual earnings per share reported by AveXis, Inc. for the previous quarter, Wall Street now forecasts -20.39 % EPS growth.

AveXis, Inc. (NASDAQ:AVXS) Ratings Coverage

Among 4 analysts covering AveXis (NASDAQ:AVXS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. AveXis had 5 analyst reports since May 13, 2016 according to SRatingsIntel. The stock of AveXis, Inc. (NASDAQ:AVXS) earned “Buy” rating by Bank of America on Friday, October 21. The stock of AveXis, Inc. (NASDAQ:AVXS) has “Market Perform” rating given on Friday, July 15 by Wells Fargo. Jefferies upgraded AveXis, Inc. (NASDAQ:AVXS) rating on Friday, August 12. Jefferies has “Buy” rating and $42 target. Jefferies maintained the stock with “Buy” rating in Monday, September 19 report. Goldman Sachs maintained AveXis, Inc. (NASDAQ:AVXS) rating on Friday, May 13. Goldman Sachs has “Buy” rating and $47 target.

More notable recent AveXis, Inc. (NASDAQ:AVXS) news were published by: Fool.com which released: “AveXis Inc.: Buy at the High?” on July 18, 2017, also Reuters.com with their article: “BRIEF-Avexis Inc CFO Thomas Dee resigns” published on October 19, 2017, Globenewswire.com published: “AveXis Reports Third Quarter 2017 Financial and Operating Results” on November 09, 2017. More interesting news about AveXis, Inc. (NASDAQ:AVXS) were released by: Nasdaq.com and their article: “Why AveXis (AVXS) Could Be Positioned for a Slump” published on December 06, 2017 as well as Globenewswire.com‘s news article titled: “AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 …” with publication date: September 29, 2017.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company has market cap of $3.16 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. It currently has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.